{"id":"sequential-icotinib-plus-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Rash/dermatitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myelosuppression (from chemotherapy component)"}]},"_chembl":{"chemblId":"CHEMBL2087361","moleculeType":"Small molecule","molecularWeight":"391.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Icotinib selectively inhibits EGFR tyrosine kinase activity, preventing downstream proliferation signals in cancer cells with EGFR mutations. The sequential combination with chemotherapy aims to leverage complementary mechanisms: targeted EGFR inhibition followed by or alternating with cytotoxic chemotherapy to improve efficacy and overcome resistance in non-small cell lung cancer.","oneSentence":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling, used sequentially with chemotherapy to treat EGFR-mutant lung cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:25.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations"}]},"trialDetails":[{"nctId":"NCT03544814","phase":"PHASE2","title":"EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2015-01-01","conditions":"Lung Adenocarcinoma, EGFR Activating Mutation","enrollment":99},{"nctId":"NCT01724801","phase":"PHASE3","title":"Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2012-10-14","conditions":"Brain Metastasis, Non Small Cell Lung Cancer","enrollment":176},{"nctId":"NCT02103257","phase":"PHASE4","title":"Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-03","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":192},{"nctId":"NCT02194556","phase":"PHASE4","title":"Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-07","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ALIMTA","DDP","Comana, BPI-2009"],"phase":"marketed","status":"active","brandName":"Sequential Icotinib Plus Chemotherapy","genericName":"Sequential Icotinib Plus Chemotherapy","companyName":"Betta Pharmaceuticals Co., Ltd.","companyId":"betta-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling, used sequentially with chemotherapy to treat EGFR-mutant lung cancer. Used for Non-small cell lung cancer with EGFR mutations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}